During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
Medpage Today on MSN3d
Combination Slows Metastatic CRC Progression Better Than Single ImmunotherapyAn immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression ...
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...
Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Australian researchers have made a breakthrough in improving the cure rate for the most common form of breast cancer. An ...
Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback